Skip to main content
EJNMMI Research
Figure 1 | EJNMMI Research

Figure 1

From: FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973

Figure 1

BRAF and MEK inhibition of FDG uptake. BRAF inhibition reduces FDG uptake associated with presence of BRAFV600E mutations, while coadministration of MEK inhibitor broadly increases the effect. (A) A panel of melanoma cell lines that were homozygous null; heterozygous or homozygous positive for BRAFV600 mutations were treated with drug for 3 days, and FDG uptake was assessed (Asterisk, lines with increased FDG uptake from vemurafenib treatment). (B) Cell lines with both BRAFV600E and RAS mutation were most susceptible to increased FDG uptake. Standard error of the mean shown, n = 4/group.

Back to article page